Landscape of MicroRNA Regulatory Network Architecture and Functional Rerouting in Cancer

Author:

Hua Xu1ORCID,Li Yongsheng2ORCID,Pentaparthi Sairahul R.2ORCID,McGrail Daniel J.1ORCID,Zou Raymond3ORCID,Guo Li1ORCID,Shrawat Aditya4ORCID,Cirillo Kara M.3ORCID,Li Qing3ORCID,Bhat Akshay2ORCID,Xu Min5ORCID,Qi Dan5ORCID,Singh Ashok6ORCID,McGrath Francis6ORCID,Andrews Steven6ORCID,Aung Kyaw Lwin2ORCID,Das Jishnu7ORCID,Zhou Yunyun8ORCID,Lodi Alessia910ORCID,Mills Gordon B.1112ORCID,Eckhardt S. Gail213ORCID,Mendillo Marc L.14ORCID,Tiziani Stefano291013ORCID,Wu Erxi251516ORCID,Huang Jason H.515ORCID,Sahni Nidhi31718ORCID,Yi S. Stephen2131920ORCID

Affiliation:

1. 1Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

2. 2Livestrong Cancer Institutes, Department of Oncology, Dell Medical School, The University of Texas at Austin, Austin, Texas.

3. 3Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas.

4. 4College of Natural Sciences, The University of Texas at Austin, Austin, Texas.

5. 5Neuroscience Institute and Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas.

6. 6Dell Medical School, The University of Texas at Austin, Austin, Texas.

7. 7Center for Systems Immunology, Department of Immunology, and Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

8. 8Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.

9. 9Department of Nutritional Sciences, College of Natural Sciences, The University of Texas at Austin, Austin, Texas.

10. 10Department of Pediatrics, Dell Medical School, The University of Texas at Austin, Austin, Texas.

11. 11Department of Cell, Developmental and Cancer Biology, School of Medicine, Oregon Health & Science University, Portland, Oregon.

12. 12Precision Oncology, Knight Cancer Institute, Portland, Oregon.

13. 13Interdisciplinary Life Sciences Graduate Programs (ILSGP), The University of Texas at Austin, Austin, Texas.

14. 14Department of Biochemistry and Molecular Genetics, and Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

15. 15Department of Surgery, Texas A & M University Health Science Center, College of Medicine, Temple, Texas.

16. 16Department of Pharmaceutical Sciences, Texas A & M University Health Science Center, College of Pharmacy, College Station, Texas.

17. 17Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

18. 18Quantitative and Computational Biosciences Program, Baylor College of Medicine, Houston, Texas.

19. 19Oden Institute for Computational Engineering and Sciences (ICES), The University of Texas at Austin, Austin, Texas.

20. 20Department of Biomedical Engineering, Cockrell School of Engineering, The University of Texas at Austin, Austin, Texas.

Abstract

Abstract Somatic mutations are a major source of cancer development, and many driver mutations have been identified in protein coding regions. However, the function of mutations located in miRNA and their target binding sites throughout the human genome remains largely unknown. Here, we built detailed cancer-specific miRNA regulatory networks across 30 cancer types to systematically analyze the effect of mutations in miRNAs and their target sites in 3′ untranslated region (3′ UTR), coding sequence (CDS), and 5′ UTR regions. A total of 3,518,261 mutations from 9,819 samples were mapped to miRNA–gene interactions (mGI). Mutations in miRNAs showed a mutually exclusive pattern with mutations in their target genes in almost all cancer types. A linear regression method identified 148 candidate driver mutations that can significantly perturb miRNA regulatory networks. Driver mutations in 3′UTRs played their roles by altering RNA binding energy and the expression of target genes. Finally, mutated driver gene targets in 3′ UTRs were significantly downregulated in cancer and functioned as tumor suppressors during cancer progression, suggesting potential miRNA candidates with significant clinical implications. A user-friendly, open-access web portal (mGI-map) was developed to facilitate further use of this data resource. Together, these results will facilitate novel noncoding biomarker identification and therapeutic drug design targeting the miRNA regulatory networks. Significance: A detailed miRNA–gene interaction map reveals extensive miRNA-mediated gene regulatory networks with mutation-induced perturbations across multiple cancers, serving as a resource for noncoding biomarker discovery and drug development.

Funder

National Institute of General Medical Sciences

Susan G. Komen

Ovarian Cancer Research Alliance

U.S. Department of Defense

Cancer Prevention and Research Institute of Texas

National Cancer Institute

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3